Subject to update:

• Lymphocyte engineering for the treatment of Hematological malignancies
• Lymphocyte engineering for the treatment of Solid tumors
• Genome editing for allogeneic ACT
• Safety switches & controlled expression
• Engineering HSC, NK, NKT and γδ T cells
• Target & receptor discovery
• Lymphocyte engineering for the treatment of HIV
• Optimizing receptor and vector design
• Non viral vectors and transposons